The primary antibodies used are as follows: anti-ABCA1 (1:500, ab18180, Abcam, Cambridge, United Kingdom), anti-PARP-1 (1:1000, 13371-1-AP, Proteintech, Wuhan, China), anti-p-PARP-1 (1:1000, MBS9206900, MyBioSource, San Diego, CA, United States), anti-LXR (1:500, ab176323, Abcam), anti-AMPK (1:1000, 10929-2-AP, Proteintech), anti-p-AMPK (1:1000, ab133448, Abcam)
Learn more about how to use them effectively:
Many breast cancer treatments, particularly certain chemotherapy regimens and hormonal therapies like tamoxifen or aromatase inhibitors, can contribute to weight gain and metabolic syndrome, making diabetes management more complex
At TrimRx, we are committed to providing you with the tools, medication, and support needed to navigate these choices
Fewer than 30 people across 3 published human trials have been studied, making large-scale safety conclusions on BPC-157 premature
Additionally, obesity and overweight are widespread: a recent report estimates that roughly 39% of adults are now obese worldwide (30% globally overweight or obese) ( [26] ), and projections suggest over half of the worlds population (4 billion people) could be obese by 2035 ( [26] )
